Cardinal Health ( (CAH) ) just unveiled an announcement.
On May 1, 2025, Cardinal Health reported its third-quarter fiscal year 2025 results, showing flat revenue at $54.9 billion compared to the previous year. However, excluding the impact of a customer contract expiration, revenue increased by 19%. The company saw a 21% increase in non-GAAP operating earnings to $807 million, driven by profit growth across all segments, and raised its fiscal year 2025 non-GAAP EPS guidance. The Pharmaceutical and Specialty Solutions segment experienced a 14% profit increase, while the Global Medical Products and Distribution segment saw a 2% revenue rise, highlighting Cardinal Health’s strong operational execution and value creation.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s stock score reflects strong revenue growth and positive future guidance, tempered by financial stress from negative equity and declining cash flow. Technical indicators suggest a stable trend, while valuation metrics indicate a slightly high price level. Acquisitions and strategic initiatives offer long-term potential, despite current challenges in specific segments.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health is a healthcare services and products company primarily engaged in the distribution of pharmaceuticals and medical products. The company focuses on providing solutions to healthcare providers and manufacturers, with a significant presence in the pharmaceutical and specialty solutions and global medical products and distribution segments.
YTD Price Performance: 20.42%
Average Trading Volume: 2,565,220
Technical Sentiment Signal: Sell
Current Market Cap: $34.13B
For detailed information about CAH stock, go to TipRanks’ Stock Analysis page.